Mr. FADZ JABAR
Venn Biosciences innovates cancer diagnostics using Artificial Intelligence (AI) and next-gen mass spectrometry, unlocking glycoproteomics for Biomarker and Target Discovery.
INTERVENN BIOSCIENCES
VICE PRESIDENT, BUSINESS DEVELOPMENTDr. Chirag Jain
Life science-focused Innovation licensing organizations looking to commercialize global innovations for the Indian and South Asian markets through a unique partnership-led model.
GCV Life
AnalystOlivier Jarry
Libera Bio develops a new family of cancer treatments based on its patented actively targeted delivery technology to intracellular targets (MPN – Multifunctional Polymeric Nanocapsules) and on novel monoclonal antibodies (e.g. anti KRAS), with the goal to have them commercialized by large biopharma companies after regulatory approval for clinical trials or early proof-of-concept in humans.
Libera Bio lead candidate aims at providing a new treatment for those highly prevalent and aggressive cancers which are driven by KRAS mutations, such as pancreatic cancer, lung cancer and colorectal cancer.
Libera Bio lead candidate aims at providing a new treatment for those highly prevalent and aggressive cancers which are driven by KRAS mutations, such as pancreatic cancer, lung cancer and colorectal cancer.
Libera Bio
MS, MBAFan Jason
Mend Biotech’s full name is Mend Biotechnology Incorporation, and its English name is Mend Biotech Inc. ( MBT). It is a multinational research institution focusing on the field of regenerative medicine to treat various skeletal-related diseases. The founding team consists of Professors and Scientists in Cedars-Sinai Medical center, UCLA and Harvard University and the kick school of medicine in USC, and the CEO of a multinational biotechnology company. In June 2020, MBT settled in CHENGDU TianFu international Bio-town as a key project introduced by Chengdu High-tech zone government. MBT received 13.5 million Chinese yuan in seed round investment by Mr. chen keming, chairman of keming noodle industry, a listed company in China. A follow on angel round is expected to generate an investment of 40 million. GMP and cGMP lab are currently under construction in both China and US.
Mend Biotech
R&D ScientistTan Jenen
Allakos is a public-traded clinical-stage biopharmaceutical company developing first-in-class antibody-based therapeutics to treat allergic and inflammatory diseases.
chunchao jia
medical device company focUnited States on blood purification